Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,101 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,794 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01243073 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera(ET/PV) | completed | Phase 2 | 20 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT01338337 | Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia(ABRAZA) | completed | Phase 2 | 40 | Asociación Andaluza de Hematología y Hemoterapia |
| 1 |
| Jan 26, 2016 |
| clinicaltrials |
| NCT00014495 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer | completed | Phase 1 / Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients(XOLMA) | completed | Phase 2 / Phase 3 | 17 | University of ZurichOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01822691 | Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00731328 | Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome | completed | Phase 2 | 15 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT02007863 | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | completed | N/A | 2 | University of MiamiOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00002718 | T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00028730 | Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT02631993 | Photochemotherapy and Graft-versus-leukemia in Acute-leukemia | completed | — | 47 | Karolinska University HospitalOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT00606216 | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy | completed | — | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00188136 | Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) | completed | Phase 2 | 32 | University Hospital Carl Gustav CarusOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01397799 | Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 24 | Kinex Pharmaceuticals Inc.INDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00039117 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00062075 | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00491634 | Treosulfan-based Conditioning for Transplantation in AML/MDS | completed | Phase 2 | 24 | Dr. Avichai Shimoni MDOTHER_GOV | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00303290 | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | completed | — | 99 | Daniel BernsteinOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT01192945 | Non-interventional Study With Azacitidin (Vidaza®)(Piaza) | completed | — | 150 | iOMEDICO AGINDUSTRY | 1 | Nov 13, 2015 | clinicaltrials |
| NCT00299156 | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | completed | Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00241241 | Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera | completed | Phase 2 | 40 | PV-NordOTHER | 1 | Oct 21, 2015 | clinicaltrials |
| NCT02006004 | Epidemiologic Registry PETHEMA LMA 2013 | completed | — | 1,000 | PETHEMA FoundationOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT00586651 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | completed | Phase 2 | 39 | CephalonINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01149408 | Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients | completed | Phase 1 | 3 | University of UtahOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT02188290 | Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | completed | — | 178 | Kiadis PharmaINDUSTRY | 6 | Oct 6, 2015 | clinicaltrials |
| NCT00479232 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | completed | Phase 1 | 71 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2015 | clinicaltrials |
| NCT00866736 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | completed | Phase 2 | 65 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01342679 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib(CMR-CML) | completed | Phase 2 | 21 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01805843 | Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia | completed | — | 16 | Medical University of GrazOTHER | 1 | Sep 9, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01127009 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01362985 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor | completed | — | 201 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 13, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia(TEAM-ET) | completed | Phase 3 | 106 | AOP Orphan Pharmaceuticals AGINDUSTRY | 5 | Jul 29, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00274781 | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 2 | 30 | The Cleveland ClinicOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Jan 26, 2016source: clinicaltrials